SCHEMBL6049188

SCHEMBL6049188

CNS(=O)(=O)c1ccc(Oc2ccc(SC)cc2)c(C2CCCN2)c1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SLC6A4 P31645 7/20 0.54
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ LMNA P02545 6/20 0.39
▸ SMN1; SMN2 Q16637 4/20 0.39
▸ HTT P42858 1/20 0.39
▸ ALDH1A1 P00352 8/20 0.39
▸ JAK2 O60674 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ HPGD P15428 1/20 0.38
▸ SLC6A2 P23975 1/20 0.37
▸ SLC6A3 Q01959 1/20 0.37
▸ MAPT P10636 1/20 0.36
▸ HTR2A P28223 1/20 0.36
▸ KCNH2 Q12809 1/20 0.36
▸ HRH3 Q9Y5N1 1/20 0.35
▸ PTGS2 P35354 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6049186 0.88 SLC6A4 (0.53) SLC6A4MEN1KMT2ALMNASMN1; SMN2
Hydrochloric Acid SCHEMBL6049202 0.87 SLC6A4 (0.52) SLC6A4MEN1KMT2ALMNASMN1; SMN2
Hydrochloric Acid SCHEMBL6049178 0.78 SLC6A4 (0.53) SLC6A4MEN1KMT2ALMNASMN1; SMN2
Hydrochloric Acid SCHEMBL6049196 0.76 MEN1 (0.48) SLC6A4MEN1KMT2ASMN1; SMN2SLC6A2
SCHEMBL2626635 0.68 SMN1; SMN2 (0.44) LMNASMN1; SMN2HTTALDH1A1MAPT
SCHEMBL6049203 0.67 KIF11 (0.48) SLC6A4MEN1KMT2ASLC6A2SLC6A3
Hydrochloric Acid SCHEMBL7522746 0.66 KIF11 (0.47) SLC6A4MEN1KMT2ASLC6A2SLC6A3
SCHEMBL1805007 0.66 SMN1; SMN2 (0.59) MEN1KMT2ALMNASMN1; SMN2HTT
Hydrochloric Acid SCHEMBL6049215 0.65 SLC6A4 (0.51) SLC6A4LMNATSHRSLC6A2SLC6A3
SCHEMBL16409298 0.65 SMN1; SMN2 (0.43) MEN1KMT2ALMNASMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1184372-B1 Phenoxyphenylheterocycle derivatives as selective serotonin reuptake inhibitors (SSRIs) PFIZER LTD (GB) 2006-04-26 — — EP claimed
US-6630504-B2 Activity as selective serotonin re- uptake inhibitors (SSRIs); for therapy and prophylaxis of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder, sexual dysfunction PFIZER INC. 2003-10-07 — — US claimed
US-20020183303-A1 Phenoxyphenylheterocyclyl derivatives as SSRIs PFIZER INC. 2002-12-05 — — US claimed
EP-1184372-A1 Phenoxyphenylheterocycle derivatives as selective serotonin reuptake inhibitors (SSRIs) Pfizer Limited (GB) 2002-03-06 — — EP claimed
EP-1184372-B1 Phenoxyphenylheterocycle derivatives as selective serotonin reuptake inhibitors (SSRIs) PFIZER LTD (GB) 2006-04-26 — — EP disclosed
US-6630504-B2 Activity as selective serotonin re- uptake inhibitors (SSRIs); for therapy and prophylaxis of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder, sexual dysfunction PFIZER INC. 2003-10-07 — — US disclosed
US-20020183303-A1 Phenoxyphenylheterocyclyl derivatives as SSRIs PFIZER INC. 2002-12-05 — — US disclosed
EP-1184372-A1 Phenoxyphenylheterocycle derivatives as selective serotonin reuptake inhibitors (SSRIs) Pfizer Limited (GB) 2002-03-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183303-A1 Phenoxyphenylheterocyclyl derivatives as SSRIs CRHR1, NR3C1, HTR6 SLC6A4 67/4885MEN1 3963/4885KMT2A 2824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback